NK cell injection with chemo after solid tumor surgery
Part of Cancer clinical trials.
This trial tests an experimental NK cell therapy (PANK-003) given along with standard chemotherapy after surgery for solid tumors. The goal is to see if adding these immune cells can help prevent the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Must be between 18 and 75 years old
- Had surgery for a solid tumor and plan to get or are getting chemo after surgery
- Must be in fairly good health with normal blood counts and organ function
- No active infections like hepatitis B, C, HIV, or syphilis
- Must not be pregnant or breastfeeding, and must use effective birth control for at least 1 year
- No unstable heart conditions in the past 6 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests a lab-made immune cell treatment (CAR-NK92 cells) for people with solid tumors that have not responded to earlier treatments. The goal is to see how safe it is and whether it can shrink tumors or help control cancer.
This trial tests a new treatment using natural killer (NK) cells, a type of immune cell, to fight advanced solid tumors. It may be an option if standard treatments have stopped working or are not available.
This trial tests whether adding an experimental cell therapy (PANK-003) to standard chemotherapy after surgery can help prevent lung cancer from coming back. It is for people with stage IIIA non-small cell lung cancer who have already had surgery and are about to start or have just started adjuvant chemotherapy.
This trial tests whether adding natural killer (NK) cell therapy to standard chemotherapy after surgery can help prevent pancreatic or bile duct cancer from coming back. It is for patients who have had their tumor completely removed and are now ready for adjuvant chemotherapy.
This trial tests an investigational NK cell therapy (NK042) for people with advanced solid tumors that have not responded to standard treatments. The aim is to see if this cellular therapy is safe and potentially effective.
This trial tests a new injection called CEL001 for people with advanced solid tumors that have not responded to or cannot tolerate standard treatments. The goal is to see if it is safe and find the right dose.
Hear when a new Solid Tumors, Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.